TKPHF

Takeda Pharmaceutical (NYSE:TAK) reported first-half fiscal 2026 results that management said were in line with expectations as the company invested in new product launches and its late-stage pipeline while using savings from a transformation program to…

Investing.com-- Takeda Pharmaceutical Co., Ltd. (TYO:4502) reported a stronger operating profit for the first half on Thursday, aided by increased cost-cutting measures and sustained weakness in the yen, which boosted returns from overseas sales.

OSAKA, Japan, October 29, 2026--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026).

OSAKA, Japan & CAMBRIDGE, Mass., October 23, 2026--Takeda (TSE:4502/NYSE:TAK) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive,…

Takeda Pharmaceutical reported new Phase 4 VERDICT data showing that intravenous ENTYVIO achieved corticosteroid free disease clearance in moderate to severe ulcerative colitis and was associated with a lower risk of UC related complications compared with…

OSAKA, Japan & CAMBRIDGE, Mass., October 15, 2026--Takeda (TSE:4502/NYSE:TAK) announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe…

OSAKA, Japan & CAMBRIDGE, Mass., October 14, 2026--Takeda presents Phase 2/3 study results for TAK-881 in primary immunodeficiency (PID), showing comparability to HYQVIA with 50% less IG volume.

Takeda Pharmaceutical has delivered a strong multi year run, and recent drug trial headlines now put a sharper spotlight on whether the current share price lines up with its sales base.

WASHINGTON & TOKYO, October 01, 2026--Corus International announced it has received a $6.4 million grant from Takeda Pharmaceutical Company Limited to help reduce climate-related health risks in Nepal.

Takeda Pharmaceutical recently reported Phase 3 data showing that its investigational oral TYK2 inhibitor, zasocitinib (TAK-279), achieved statistically superior complete skin clearance versus deucravacitinib and outperformed apremilast in adults with moderate-to-severe plaque psoriasis, with results presented at the 2026 European Academy of Dermatology & Venereology Congress.

Takeda Pharmaceutical (TSE:4502) has put its psoriasis pipeline in the spotlight after new Phase 3 LATITUDE data showed that investigational pill zasocitinib outperformed deucravacitinib on skin clearance measures in adults with moderate to severe plaque psoriasis.

Takeda (TAK) said Wednesday that its experimental pill zasocitinib showed superior results compared